Cyclopharm’s Technegas Gains US Guideline Nod, Boosting Market Prospects
Cyclopharm’s Technegas has been recognised as the preferred ventilation agent in a pivotal draft US lung imaging guideline, signalling a major boost for its adoption in American clinical practice.
- Technegas named preferred ventilation agent in US draft lung imaging guideline
- Guideline developed by leading nuclear medicine societies across US, Europe, Australia, and Canada
- Recognition expected to accelerate Technegas adoption and hospital integration in the US
- Guideline expands Technegas use beyond pulmonary embolism to multiple lung conditions
- Final guideline publication anticipated in coming months after public consultation
A Milestone for Technegas in US Clinical Practice
Cyclopharm Limited has achieved a significant milestone with its flagship product, Technegas, being explicitly recognised as the preferred ventilation agent in a newly released draft guideline for lung imaging in the United States. This draft, issued by the US Society of Nuclear Medicine and Molecular Imaging (SNMMI) in collaboration with the American College of Nuclear Medicine (ACNM) and international experts, marks a pivotal moment for Cyclopharm’s penetration into the US healthcare market.
Guideline Reflects Over a Decade of Progress
The Procedure Standard and Guideline for Ventilation-Perfusion Pulmonary Scintigraphy is the first comprehensive update since 2012, reflecting more than ten years of clinical and technological advances. It highlights Technegas as a clinical advancement that enhances diagnostic accuracy and utility in lung scintigraphy, particularly for pulmonary embolism assessment. The guideline’s multinational authorship lends it considerable authority, setting a new benchmark for clinical practice.
Broader Clinical Applications and Technological Integration
Beyond its established role in pulmonary embolism diagnosis, the guideline acknowledges the expanding clinical applications of Technegas, including chronic lung disease follow-up, asthma, COPD, pulmonary hypertension, and lung transplantation. It also underscores the integration of advanced imaging techniques such as SPECT and SPECT/CT, alongside emerging technologies like artificial intelligence, which collectively enhance the functional assessment of lung ventilation.
Implications for Market Adoption and Hospital Procurement
Cyclopharm’s CEO James McBrayer emphasised the guideline’s importance as a foundational reference that will influence clinical behaviour, hospital procurement, and reimbursement decisions. The formal recognition of Technegas is expected to drive accelerated demand and broader institutional adoption across US hospitals, potentially translating into significant revenue growth for Cyclopharm in a key market.
Next Steps and Market Watch
The draft guideline is currently open for public consultation and may undergo refinements before final publication in the coming months. Investors and industry watchers will be keen to monitor the final wording and the speed at which US healthcare providers integrate Technegas into their standard workflows, as well as how competitors respond to this endorsement.
Bottom Line?
With Technegas poised for wider US adoption, Cyclopharm stands at the threshold of a new growth chapter; but the final guideline and market uptake will be critical to watch.
Questions in the middle?
- When will the final US lung imaging guideline be published and what changes might it include?
- How quickly will US hospitals and health systems adopt Technegas following this endorsement?
- What competitive responses might emerge from other nuclear medicine ventilation agents?
